Current and emerging strategies to increase the efficacy of ionizing radiation in the treatment of cancer

Expert Opinion on Drug Discovery

Volumn 9, Issue 2, 2014, Pages 167-181

  Berdis, Anthony J ^a  

^a CLEVELAND STATE UNIVERSITY   (United States)

Author keywords

Chemosensitizers; Chemotherapy; DNA repair inhibitors; Ionizing radiation; Novel therapeutic agents

Indexed keywords

ANTIMETABOLITE; CISPLATIN; DNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; NUCLEIC ACID; NUCLEOSIDE ANALOG; RADIOSENSITIZING AGENT;

APOPTOSIS; CANCER THERAPY; CELL DEATH; CYTOTOXICITY; DNA DAMAGE; DNA END JOINING REPAIR; DNA REPAIR; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; HOMOLOGOUS RECOMBINATION; HUMAN; HYPOXIA; IONIZING RADIATION; NONHUMAN; PRIORITY JOURNAL; RADIOSENSITIZATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DEATH; COMBINED MODALITY THERAPY; DNA DAMAGE; HUMANS; NEOPLASMS; RADIATION, IONIZING; TREATMENT OUTCOME;

EID: 84893036772     PISSN: 17460441     EISSN: 1746045X     Source Type: Journal    
DOI: 10.1517/17460441.2014.876987     Document Type: Review

References (94)

1. Harrington KJ, Nutting CM. Interactions between ionizing radiation and drugs in head and neck cancer: how can we maximize the therapeutic index? Curr Opin Investig Drugs 2002;3:807-11
2. Ronckers CM, Erdmann CA, Land CE. Radiation and breast cancer: a review of current evidence. Breast Cancer Res 2005;7:21-32
3. Lyman GH. Impact of chemotherapy dose intensity on cancer patient outcomes. J Natl Compr Canc Netw 2009;7:99-108
4. Ward JF. The yield of DNA doublestrand breaks produced intracellularly by ionizing radiation: a review. Int J Radiat Biol 1990;57:1141-50
5. Clowse ME, Wigley FM. Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis. J Rheumatol 2003;30:1341-3
6. Zahn KE, Wallace SS, Doublié S. DNA polymerases provide a canon of strategies for translesion synthesis past oxidatively generated lesions. Curr Opin Struct Biol 2011;21:358-69
7. Allan JM, Travis LB. Mechanisms of therapy-related carcinogenesis. Nat Rev Cancer 2005;5:943-55
8. Chang H, Liaw CC, Chang HK. Therapy-related acute myeloid leukemia after concurrent chemoradiotherapy for esophageal cancer: report of two cases. Tumori 2009;95:371-3
9. von Sonntag C. The chemistry of free-radical-mediated DNA damage. Basic Life Sci 1991;58:287-317
10. Goodhead DT. The initial physical damage produced by ionizing radiations. Int J Radiat Biol 1989;56:623-34
11. Shikazono N, Noguchi M, Fujii K, et al. The yield, processing, and biological consequences of clustered DNA damage induced by ionizing radiation. J Radiat Res 2009;50:27-36
12. Blue J, Cadet T, Douki I, Ravanat J-L. Oxidatively generated damage to the guanine moiety of DNA: mechanistic aspects and formation in cells. Acc Chem Res 2008;41:1075-83
13. Greenstock CL. Radiation and aging: free radical damage, biological response and possible antioxidant intervention. Med Hypotheses 1993;41:473-82
14. Sutherland BM, Bennett PV, Saparbaev M, et al. Clustered DNA damages as dosemeters for ionising radiation exposure and biological responses. Radiat Prot Dosimetry 2001;97:33-8
15. Eccles LJ, O'Neill P, Lomax ME. Delayed repair of radiation induced clustered DNA damage: friend or foe? Mutat Res 2011;711:134-41
16. Lieber MR. The mechanism of doublestrand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 2010;79:181-211
17. Shrivastav M, De Haro LP, Nickoloff JA. Regulation of DNA double-strand break repair pathway choice. Cell Res 2008;18:134-47
18. Delacote F, Lopez BS. Importance of the cell cycle phase for the choice of the appropriate DSB repair pathway, for genome stability maintenance: the trans-S double-strand break repair model. Cell Cycle 2008;7:33-8
19. Durant ST, Nickoloff JA. Good timing in the cell cycle for precise DNA repair by BRCA1. Cell Cycle 2005;4:1216-22
20. Barker CA, Powell SN. Enhancing radiotherapy through a greater understanding of homologous recombination. Semin Radiat Oncol 2010;20:267-73
21. Critchlow SE, Jackson SP. DNA endjoining: from yeast to man. Trends Biochem Sci 1998;23:394-8
22. Barr FG. Translocations, cancer and the puzzle of specificity. Nat Genet 1998;19:121-4
23. Wickman G, Julian L, Olson MF. How apoptotic cells aid in the removal of their own cold dead bodies. Cell Death Differ 2012;19:735-42
24. Portugal J, Mansilla S, Bataller M. Mechanisms of drug-induced mitotic catastrophe in cancer cells. Curr Pharm Des 2010;16:69-78
25. Palumbo S, Comincini S. Autophagy and ionizing radiation in tumors: the "survive or not survive" dilemma. J Cell Physiol 2013;228:1-8
26. Fertil B, Dertinger H, Courdi A, Malaise EP. Mean inactivation dose: a useful concept for intercomparison of human cell survival curves. Radiat Res 1984;99:73-84
27. Thomlinson RH, Gray LH. The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955;9:539-49
28. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18-24
29. Dizdaroglu M, Jaruga P. Mechanisms of free radical-induced damage to DNA. Free Radic Res 2102;46:382-419
30. Wardman P. Chemical radiosensitizers for use in radiotherapy. Clin Oncol 2007;19:397-417
31. Buchko GW, Weinfeld M. Influence of nitrogen, oxygen, and nitroimidazole radiosensitizers on DNA damage induced by ionizing radiation. Biochemistry 1993;32:2186-93
32. Overgaard J, Eriksen JG, Nordsmark M, et al. Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. Lancet Oncol 2005;6:757-64
33. Dobrowsky W, Huigol NG, Jayatilake RS, et al. AK-2123 (Sanazol) as a radiation sensitizer in the treatment of stage III cervical cancer: results of an IAEA multicentre randomised trial. Radiother Oncol 2007;82:24-9
34. Papadopoulou MV, Bloomer WD. Nitroimidazole-based bioreductive compounds bearing a quinazoline or a naphthyridine chromophore. Anticancer Drugs 2009;20:493-502
35. Lieber MR. The mechanism of doublestrand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem 2010;79:1-31
36. Li GC, He F, Shao X, et al. Adenovirus-mediated heat-activated antisense Ku70 expression radiosensitizes tumor cells in vitro and in vivo. Cancer Res 2003;63:3268-74
37. Peng Y, Zhang Q, Nagasawa H, et al. Silencing expression of the catalytic subunit of DNA-dependent protein kinase by small interfering RNA sensitizes human cells for radiationinduced chromosome damage, cell killing, and mutation. Cancer Res 2002;62:6400-4
38. Peterson SR, Kurimasa A, Oshimura M, et al. Loss of the catalytic subunit of the DNA-dependant protein kinase in DNA double-strand-break-repair mutant mammalian cells. Proc Natl Acad Sci USA 1995;92:3171-4
39. Du L, Zhou LJ, Pan XJ, et al. Radiosensitization and growth inhibition of cancer cells mediated by a scFv antibody gene against DNA-PKcs in vitro and in vivo. Radiat Oncol 2010;5:70
40. Panda H, Jaiswal AS, Corsino PE, et al. Amino acid Asp181 of 50-flap endonuclease 1 is a useful target for chemotherapeutic development. Biochemistry 2009;48:9952-8
41. Neijenhuis S, Verwijs-Janssen M, van den Broek LJ, et al. Targeted radiosensitization of cells expressing truncated DNA polymerase {beta}. Cancer Res 2010;70:8706-14
42. Stachelek GC, Dalal S, Donigan KA, et al. Potentiation of temozolomide cytotoxicity by inhibition of DNA polymerase beta is accentuated by BRCA2 mutation. Cancer Res 2010;70:409-17
43. Sedletska Y, Giraud-Panis M-J, Malinge J-M. Cisplatin is a DNAdamaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways. Curr Med Chem Anticancer Agents 2005;5:251-65
44. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin- DNA adducts. Chem Rev 1999;99:2467-98
45. Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987;34:155-66
46. Lin X, Howell SB. DNA mismatch repair and p53 function are major determinants of the rate of development of cisplatin resistance. Mol Cancer Ther 2006;5:1239-47
47. Shimodaira H, Yoshioka-Yamashita A, Kolodner RD, Wang JY. Interaction of mismatch repair protein PMS2 and the p53-related transcription factor p73 in apoptosis response to cisplatin. Proc Natl Acad Sci USA 2003;100:2420-5
48. Lin X, Ramamurthi K, Mishima M, et al. p53 modulates the effect of loss of DNA mismatch repair on the sensitivity of human colon cancer cells to the cytotoxic and mutagenic effects of cisplatin. Cancer Res 2001;61:1508-16
49. Thoms J, Bristow RG. DNA repair targeting and radiotherapy: a focus on the therapeutic ratio. Semin Radiat Oncol 2010;20:217-22
50. Sedletska Y, Fourrier L, Malinge J-M. Modulation of MutS ATP-dependent functional activities by DNA containing a cisplatin compound lesion (base damage and mismatch). J Mol Biol 2007;369:27-40
51. Bartelink H, Begg A, Martin JC, et al. Towards prediction and modulation of treatment response. Radiother Oncol 1999;50:1-11
52. Lillo O, Bracesco N, Nunes E. Lethal and mutagenic interactions between gamma-rays, cisplatin and etoposide at the cellular and molecular levels. Int J Radiat Biol 2011;87:222-30
53. Yang YC, Chao KS, Lin CP, et al. Oxaliplatin regulates DNA repair responding to ionizing radiation and enhances radiosensitivity of human cervical cancer cells. Int J Gynecol Cancer 2009;19:782-6
54. Tippayamontri T, Kotb R, Paquette B, Sanche L. Synergism in concomitant chemoradiotherapy of cisplatin and oxaliplatin and their liposomal formulation in the human colorectal cancer HCT116 model. Anticancer Res 2012;32:4395-404
55. Rezaee M, Hunting DJ, Sanche L. New insights into the mechanism underlying the synergistic action of ionizing radiation with platinum chemotherapeutic drugs: the role of lowenergy electrons. Int J Radiat Oncol Biol Phys 2013;87(4):847-53
56. Parker WB. Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. Chem Rev 2009;109:2880-93
57. Braess J, Jahns-Streubel G, Schoch C, et al. Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemia. Br J Haematol 2001;113:975-82
58. Yamauchi T, Kawai Y, Ueda T. Inhibition of nucleotide excision repair by fludarabine in normal lymphocytes in vitro, measured by the alkaline single cell gel electrophoresis (Comet) assay. Jpn J Cancer Res 2002;93:567-73
59. Jiang HY, Hickey RJ, Abdel-Aziz W, Malkas LH. Effects of gemcitabine and araC on in vitro DNA synthesis mediated by the human breast cell DNA synthesome. Cancer Chemother Pharmacol 2000;45:320-8
60. Durkacz BW, Omidiji O, Gray DA, Shall S. (ADP-ribose) participates in DNA excision repair. Nature 1980;283:593-6
61. Penning TD, Zhu GD, Gandhi VB, et al. Discovery of the poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2- methylpyrrolidin-2-yl]-1Hbenzimidazole- 4-carboxamide (ABT-888) for the treatment of cancer. J Med Chem 2009;52:514-23
62. Menear KA, Adcock C, Boulter R, et al. 4-[3-(4- cyclopropanecarbonylpiperazine- 1-carbonyl)-4-fluorobenzyl]-2Hphthalazin- 1-one: a novel bioavailable inhibitor of poly(ADP-ribose) polymerase-1. J Med Chem 2008;51:6581-91
63. Ferraris DV. Evolution of poly(ADPribose) polymerase-1 (PARP1) inhibitors. From concept to clinic. J Med Chem 2010;53:4561-84
64. Javle NJ, Curtin M. The potential for poly (ADP-ribose) polymerase inhibitors in cancer therapy. Ther Adv Med Oncol 2011;3:257-67
65. Ben-Hur E, Chen CC, Elkind MM. Inhibitors of poly (adenosine diphosphoribose) synthetase, examination of metabolic perturbations, and enhancement of radiation response in Chinese hamster cells. Cancer Res 1985;45:2123-7
66. Dungey FA, Loser DA, Chalmers AJ. Replication-dependent radiosensitization of human glioma cells by inhibition of poly(ADP-Ribose) polymerase: mechanisms and therapeutic potential. Int J Radiat Oncol Biol Phys 2008;72:1188-97
67. Saleh-Gohari N, Bryant HE, Schultz N, et al. Spontaneous homologous recombination is induced by collapsed replication forks that are caused by endogenous DNA single-strand breaks. Mol Cell Biol 2005;25:7158-69
68. Harper JV, Anderson JA, O'Neill P. Radiation induced DNA DSBs: contribution from stalled replication forks? DNA Repair (Amst) 2010;9:907-13
69. Mitchell J, Smith GC, Curtin NJ. Poly (ADP-ribose) polymerase-1 and DNAdependent protein kinase have equivalent roles in double strand break repair following ionising radiation. Int J Radiat Oncol Biol Phys 2009;75:1520-7
70. Leopold WR, Sebolt-Leopold JS. Chemical approaches to improved radiotherapy. In: Valeriote FA, Corbett TH, Baker LH, editors. Cytotoxic anticancer drugs: models and concepts for drug discovery and development. Kluwer; Boston; 1992. p. 179-96
71. Calabrese CR, Almassy R, Barton S, et al. Preclinical evaluation of a novel poly(ADP-ribose) polymerase-1 (PARP1) inhibitor, AG14361, with significant anticancer chemo- and radio-sensitization activity. J Natl Cancer Inst 2004;96:56-67
72. Wang L, Mason KA, Ang KK, et al. MK-4827, a PARP1/-2 inhibitor, strongly enhances response of human lung and breast cancer xenografts to radiation. Invest New Drugs 2012;30:2113-20
73. Senra JM, Telfer BA, Cherry KE, et al. Inhibition of PARP1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 2011;10:1949-58
74. Mehta MP, Curran WJ, Wang D, et al. Phase I safety and pharmacokinetic (PK) study of veliparib in combination with whole brain radiation therapy (WBRT) in patients (pts) with brain metastases. J Clin Oncol 2012;3:s2013
75. Pentimalli F, Giordano A. Promises and drawbacks of targeting cell cycle kinases in cancer. Discov Med 2009;8:177-80
76. Raghavan P, Tumati V, Yu L, et al. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of nonsmall cell lung carcinoma cells. Int J Radiat Oncol Biol Phys 2012;84:e507-14
77. Ma Z, Yao G, Zhou B, et al. The Chk1 inhibitor AZD7762 sensitises p53 mutant breast cancer cells to radiation in vitro and in vivo. Mol Med Rep 2012;6:897-903
78. Kuroda S, Urata Y, Fujiwara T. Ataxia-telangiectasia mutated and the Mre11-Rad50-NBS1 complex: promising targets for radiosensitization. Acta Med Okayama 2012;66:83-92
79. Chakraborty M, Gelbard A, Carrasquillo J, et al. Systemic radioimmunotherapy in synergy with vaccine renders antitumor effects in a preclinical model. AACR Annual Proceedings; 2006. p. 1165
80. Demaria S, Formenti SC. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 2007;83:819-25
81. Demaria S, Bhardwaj N, McBride WH, Formenti SC. Combining radiotherapy and immunotherapy: a revived partnership. Int J Radiat Oncol Biol Phys 2005;63:655
82. Tesniere A, Panaretakis T, Kepp O, et al. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008;15:3-12
83. Demaria S, Santori FR, Ng B, et al. Select forms of tumor cell apoptosis induce dendritic cell maturation. J Leukoc Biol 2005;77:361-8
84. Chi KH, Liu SJ, Li CP, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005;28:129-35
85. Kumar A, Zhang X, Liang XJ. Gold nanoparticles: emerging paradigm for targeted drug delivery system. Biotechnol Adv 2013;31:593-606
86. Mukerjee A, Ranjan AP, Vishwanatha JK. Combinatorial nanoparticles for cancer diagnosis and therapy. Curr Med Chem 2012;19:3714-21
87. Chang MY, Shiau AL, Chen YH, et al. Increased apoptotic potential and doseenhancing effect of gold nanoparticles in combination with single-dose clinical electron beams on tumor-bearing mice. Cancer Sci 2008;99:1479-84
88. Li YJ, Perkins AL, Su Y, et al. Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation. Proc Natl Acad Sci USA 2012;109:4092-7
89. Butterworth KT, Coulter JA, Jain S, et al. Evaluation of cytotoxicity and radiation enhancement using 1.9 nm gold particles: potential application for cancer therapy. Nanotechnology 2010;21:295101
90. Butterworth KT, McMahon SJ, Currell FJ, Prise KM. Physical basis and biological mechanisms of gold nanoparticle radiosensitization. Nanoscale 2012;21:4830-8
91. Craig S, Gao L, Lee I, et al. Gold-containing indoles as anticancer agents that potentiate the cytotoxic effects of ionizing radiation. J Med Chem 2012;55:2437-51
92. Chang UK, Lee DH. Stereotactic radiosurgery for spinal neoplasms: current status and future perspective. J Neurosurg Sci 2013;57:87-101
93. Nagata Y. Stereotactic body radiotherapy for early stage lung cancer. Cancer Res Treat 2013;45:155-61
94. Clémenson C, Chargari C, Deutsch E. Combination of vascular disrupting agents and ionizing radiation. Crit Rev Oncol Hematol 2013;86:143-60